SIVEXTRO INJECTION Rx
Generic Name and Formulations:
Tedizolid phosphate 200mg; lyophilized pwd for IV infusion after reconstitution; preservative-free.
Merck & Co., Inc.
Indications for SIVEXTRO INJECTION:
Susceptible acute bacterial skin and skin structure infections (ABSSSI).
≥18yrs: Infuse 200mg once daily over 1 hour for 6 days. Switching from IV to oral: no dose adjustment necessary.
<18yrs: not established.
Not adequately evaluated in patients with neutropenia (ANC <1000 cells/mm3); consider alternate therapies. Risk of C. difficile-associated diarrhea; discontinue if suspected or confirmed. Pregnancy (Cat.C). Nursing mothers.
Tabs: May potentiate oral BCRP substrates; consider interrupting co-administered substrates esp. those with narrow therapeutic index (eg, methotrexate, topotecan); monitor if coadministration (including rosuvastatin) is necessary.
Nausea, headache, diarrhea, vomiting, dizziness.
Tabs—6 (blister pack), 30; single-use vials—10
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Serious Adverse Events Profile for Cladribine Confirmed With Extended Data
- Unintended Pregnancy Common in Women With Epilepsy
- Aggressive Blood Pressure Lowering in Intracerebral Hemorrhage May Be Harmful
- Risk of Opioid-Benzodiazepine Overlap Up for Dual Prescribing
- Minority Residents Experience Burdens Linked to Race/Ethnicity
- Tips Provided for Budgeting in Medical Residency